Semelev Viacheslav (candidate of medical sciences, associate professor of the chair, Military – Medical Academy C.M. Kirov)
Tyrenko Vadim (doctor of medical sciences, head of the chair, Military – Medical Academy C.M. Kirov )
Yurkin Alexander (candidate of medical sciences, assistant of the chair, Military – Medical Academy C.M. Kirov)
Tarakanova Lyubov (haematologist, Military – Medical Academy C.M. Kirov)
Nikitin Vladimir (doctor of medical sciences, head of immunological laboratory, Military – Medical Academy C.M. Kirov)
Sukhina Irina (candidate of medical sciences, head of laboratory, Military – Medical Academy C.M. Kirov)
Egorova Elizaveta (candidate of medical sciences, head of laboratory, Military – Medical Academy C.M. Kirov)
Voloshin Sergey (candidate of medical sciences, head of clinical department Russian Research Institute of Hematology and Transfusiology)
Uspenskaya Olga (candidate of medical sciences, head of the division, Leningrad regional Clinical, St. Petersburg)
Karyagina Elena (head of the division, City Hospital No. 15, St. Petersburg)
| |
Patients with acute myeloid leukemia younger than 60 years before the onset of antitumor therapy during the phases of primary attack of disease, induction and consolidation showed multidirectional changes in the hemostasis system, manifested in the hypocoagulation and activation of the intravascular coagulation process, reduction in the activity of the anticoagulant system during an increase in the activity of an fibrinolysis, decrease in the number of platelets with an increase in their aggregation function. At the same time, the most significant changes in the hemostatic system were observed at the phases of the primary attack of the disease and the development of relapse. In the process of therapy and achieving remission of the disease, there was a gradual tendency to reduce the severity of changes in the hemostasis system and achieve the level of the control group. In general, the status of hemostasis in most patients with acute myeloid leukemia younger than 60 years before the next stage of therapy allowed for courses of antitumor therapy.
Keywords:acute myeloid leukemia, hemostasis indicators, functional platelet activity
|
|
| |
|
Read the full article …
|
Citation link:
Semelev V. , Tyrenko V. , Yurkin A. , Tarakanova L. , Nikitin V. , Sukhina I. , Egorova E. , Voloshin S. , Uspenskaya O. , Karyagina E. Hemorrhagic complications in patients with acute myeloid leukemia younger 60 years and their prediction by hemostasis indicators // Современная наука: актуальные проблемы теории и практики. Серия: Естественные и Технические Науки. -2019. -№1. -С. 124-134 |
|
|
